Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Biometrics Neural topic
No spam. Unsubscribe anytime.
Committee hears calls for rules on biometric and neural technologies; bills would add accountability
Summary
Testimony pressed the joint committee to regulate private use of biometric recognition and emerging consumer neurotechnology: sponsors proposed fiduciary responsibilities for firms using biometrics and a Neural Data Privacy Act to limit collection, sale and reuse of neural signals.
Legislators heard testimony urging new guardrails for private uses of biometric recognition and emerging consumer neurotechnology. Witnesses described how facial recognition, biometric profiling and brain‑data devices can identify and track people without their consent, and argued for new statutory protections.
Biometric recognition: Senator testifiers and privacy advocates urged accountability rules for facial recognition used by private firms. Supporters proposed stricter limits on commercial face‑recognition and broader enforcement authority to stop misuse that could expose workers, customers and protestors to tracking and reprisals. Several witnesses asked the committee to require transparency and affect legal remedies where firms misuse biometric identifiers.
Neural data: Representatives of the NeuroRights Foundation and clinical neurologists urged the committee to consider a Massachusetts Neural Data Privacy Protection Act (H.103). They described consumer brain‑data devices (headbands, earbuds) that record neural signals and argued those data are “medical‑grade” and extremely sensitive. Witnesses said the law should treat neural data as sensitive, bar sale without consent, and require protections comparable to medical records when devices are used outside clinical settings.
Why proponents pressed urgency: Several speakers noted near‑term market developments: device makers and major technology platforms are developing consumer neurotech and in‑ear sensors; dataset aggregation plus advances in generative AI increase the risk that decoded neural signals could reveal diagnoses, emotions or thoughts in ways that could be exploited by advertisers, insurers or governments.
Industry and technical positions: Some industry witnesses said innovation and competitiveness are priorities but that clear rules would create market stability and consumer trust. Witnesses urged narrow, interoperable rules that preserve clinical research and medical uses while protecting consumers in commercial deployments.
Next steps: The committee requested written technical briefs on hardware capabilities, proposed definitions of ‘‘neural data’’ and on how HIPAA and FDA rules intersect with consumer devices.
